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ABSTRACT: The design, synthesis, and characterization of
enterobactin−antibiotic conjugates, hereafter Ent-Amp/Amx,
where the β-lactam antibiotics ampicillin (Amp) and
amoxicillin (Amx) are linked to a monofunctionalized
enterobactin scaﬀold via a stable poly(ethylene glycol) linker
are reported. Under conditions of iron limitation, these
siderophore-modiﬁed antibiotics provide enhanced anti-
bacterial activity against Escherichia coli strains, including
uropathogenic E. coli CFT073 and UTI89, enterohemorrhagic E. coli O157:H7, and enterotoxigenic E. coli O78:H11, compared
to the parent β-lactams. Studies with E. coli K-12 derivatives defective in ferric enterobactin transport reveal that the enhanced
antibacterial activity observed for this strain requires the outer membrane ferric enterobactin transporter FepA. A remarkable
1000-fold decrease in minimum inhibitory concentration (MIC) value is observed for uropathogenic E. coli CFT073 relative to
Amp/Amx, and time-kill kinetic studies demonstrate that Ent-Amp/Amx kill this strain more rapidly at 10-fold lower
concentrations than the parent antibiotics. Moreover, Ent-Amp and Ent-Amx selectively kill E. coli CFT073 co-cultured with
other bacterial species such as Staphylococcus aureus, and Ent-Amp exhibits low cytotoxicity against human T84 intestinal cells in
both the apo and iron-bound forms. These studies demonstrate that the native enterobactin platform provides a means to
eﬀectively deliver antibacterial cargo across the outer membrane permeability barrier of Gram-negative pathogens utilizing
enterobactin for iron acquisition.
■ INTRODUCTION
Bacterial infections as well as the emergence and spread of
antibiotic resistance in human pathogens are serious public
health problems in hospital and community settings across the
globe.1 New strategies to prevent and treat bacterial infections
are needed, including methods to overcome antibacterial
resistance that results from the outer membrane permeability
barrier in Gram-negative organisms and targeting approaches
that aﬀord species- or pathogen-speciﬁc therapeutics.2−8
Metal ions are essential nutrients for all organisms. Almost all
bacterial species have a metabolic iron requirement and
therefore employ various strategies to acquire this metal ion
when colonizing.9,10 Siderophores are high-aﬃnity Fe(III)
chelators that are produced by bacteria under conditions of
iron limitation, such as those encountered in the vertebrate
host, to scavenge this metal ion from the environment.10,11
Siderophore producers also express dedicated ferric sidero-
phore import machinery and employ various mechanisms to
release siderophore-bound iron following cellular uptake (e.g.,
reductive and/or hydrolytic release mediated by reductases
and/or esterases, respectively).12 Numerous studies support the
importance of siderophore-based iron acquisition during
bacterial infections.13−19 Thus, the potential of using sidero-
phores,20−25 or targeting siderophore biosynthetic and trans-
port machineries,26−28 in therapeutic development continues to
attract signiﬁcant interest. Of particular relevance to the
advances described herein are prior investigations pertaining
to the development of siderophore−antibiotic conjugates for
“Trojan horse” antibiotic delivery.29−58 This strategy has
received particular attention for the delivery of antibiotics
into Gram-negative bacteria because these organisms are
inherently less sensitive to many antibiotics used in the clinic
as a result of the outer membrane permeability barrier.6−8
Both native siderophores and synthetic siderophore mimics
have been evaluated as platforms for therapeutic develop-
ment.20−25,59,60 In the clinic, the native siderophore desferri-
oxamine B is used for iron-chelation therapy in patients with
iron overload. Several antibiotic small molecules found in
Nature called “sideromycins” provide inspiration for synthetic
siderophore−antibiotic conjugates.61 The sideromycins are
secondary metabolites comprised of a siderophore moiety
and a toxic cargo; the siderophore portion targets sideromycins
to bacterial strains expressing the appropriate siderophore
receptor. Microcin E492m, a siderophore−antibiotic conjugate
produced by a clinical isolate of Klebsiella pneumoniae, is an 84-
residue antibacterial peptide with a glucosylated enterobactin
(Ent, Figure 1) derivative attached to its C-terminus that
exhibits enhanced antibacterial activity against strains express-
ing the enterobactin receptor FepA.62 From the standpoints of
antibacterial activity and therapeutic potential, studies of
synthetic siderophore−antibiotic conjugates have provided
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the community with mixed results, causing some skepticism
about the potential of siderophore-based approaches despite
the successful utilization of such molecules by Nature.
Many of the failures encountered with early and recent
studies of siderophore-based antibiotic delivery may be
attributed, at least in part, to (i) use of non-native siderophores
with relatively low Fe(III) aﬃnities and/or compromised
receptor recognition;63 (ii) modiﬁcation of antibiotics such that
the antibacterial activity is attenuated or lost com-
pletely;42,44,51,58 (iii) bridging the siderophores and antibiotics
with problematic linkers, including linkers designed for drug
release that are either too stable or too labile, the latter of which
promotes premature release;25,45−48 and (iv) antibiotic
resistance.34,63 Nevertheless, the lessons of many unsuccessful
studies highlight the complexity of siderophore-based ther-
apeutic development and provide a foundation for inventing
improved next-generation approaches. Many of the issues
described above may be overcome by careful molecular design
and biological evaluation. In particular, the selection of
appropriate native siderophore platforms and modiﬁcation of
these platforms in ways that do not compromise iron binding
or receptor recognition, installation of an antibacterial cargo in
such a manner that antibacterial activity is retained, and the
development and application of assays that aﬀord insight into
the fate of siderophore−antibiotic conjugates are critical to the
overall success of this approach. Along such lines, a recent and
insightful study by Pﬁzer addressed complications associated
with using relatively low-molecular-weight siderophore mimics
in vivo.63 Their results indicate that competition between the
siderophore-conjugated monobactam MB-1 and native sidero-
phores resulted in poor in vivo eﬃcacy against Pseudomonas
aeruginosa and provide support for designing and evaluating
siderophore−antibiotic conjugates based on native siderophore
platforms. One recent and successful example based on a native
siderophore platform is a mycobactin−artemisinin conjugate
that exhibits enhanced antibacterial activity against Mycobacte-
rium tuberculosis compared to unmodiﬁed artemisinin.64
Enterobactin (Ent, Figure 1) is a triscatecholate siderophore
biosynthesized by enteric bacteria and used for iron acquisition
in the vertebrate host.65 Motivated by the importance of Ent in
the host/microbe interaction as well as the decades of
investigations pertaining to its (bio)synthesis, coordination
chemistry, and biology, in prior work we reported a synthetic
route to monofunctionalized Ent platforms.66 Moreover, we
established that the native Ent platform, when monofunction-
alized at the C5 position of one catecholate ring (Figure 1),
aﬀords delivery of nontoxic small-molecule cargo across the
outer membrane of Gram-negative organisms that express Ent
uptake machinery (e.g., FepABCDG of Escherichia coli).66 As
described herein, this proof-of-concept study motivated us to
demonstrate that Ent eﬀectively delivers antibacterial cargo to
organisms that utilize Ent for iron acquisition, thereby
providing antibiotic targeting to speciﬁc sub-populations and
a means to address antibiotic resistance that results from the
Gram-negative outer membrane permeability barrier.
In this work, we present the syntheses and characterization of
siderophore−antibiotic conjugates based on the native Ent
platform that harbor the clinically relevant β-lactam antibiotics
ampicillin (Amp) and amoxicillin (Amx). These antibiotics
block cell wall biosynthesis by inhibiting transpeptidases, also
named penicillin binding proteins (PBPs), located in the
periplasm of E. coli. We report that the Ent-β-lactam conjugates
exhibit signiﬁcantly enhanced antibacterial activity (up to 1000-
fold) against pathogenic E. coli and provide more rapid cell-
killing than the parent β-lactams as a result of Ent-mediated
delivery to the periplasm. Moreover, in proof-of-concept
studies for species-speciﬁc killing, these conjugates selectively
kill E. coli in the presence of Staphylococcus aureus, a Gram-
positive organism that is more susceptible to the parent β-
lactams. These studies support the notion that native
siderophore platforms provide an eﬀective means to target
molecular cargo to siderophore-utilizing organisms and to
hijack siderophore uptake machinery to deliver cargos,
including antibiotics, across the outer membrane permeability
barrier of Gram-negative microbes.
■ EXPERIMENTAL SECTION
Synthetic Reagents. Dimethylformamide (DMF) and dichloro-
methane (CH2Cl2) were obtained from a VAC solvent puriﬁcation
system (Vacuum Atmospheres). Anhydrous dimethyl sulfoxide
(DMSO) was purchased from Sigma-Aldrich and used as received.
HPLC-grade acetonitrile (MeCN) was purchased from EMD. L-Ent
1,67 the D-enantiomer of benzyl-protected Ent-CO2H 2, and the
benzyl-protected Ent-PEG3-N3 3 were synthesized according to
previously reported procedures.66 11-Azido-3,6,9-trioxaundecan-1-
amine was purchased from Fluka. All other chemicals and solvents
were purchased from Sigma-Aldrich or Alfa Aesar in the highest
available purity and used as received. General synthetic methods are
provided as Supporting Information.
N1-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-N3-
((3S,7S,11S)-7,11-bis(2,3-dihydroxybenzamido)-2,6,10-trioxo-
1,5,9-trioxacyclododecan-3-yl)-4,5-dihydroxyisophthalamide
(4). Benzyl-protected Ent-azide 3 (80 mg, 55 μmol) and pentamethyl-
benzene (PMB, 147 mg, 990 μmol) were dissolved in 5 mL of
anhydrous CH2Cl2 to give a light yellow solution. This solution was
cooled to −78 °C in an acetone/dry ice bath under N2, and BCl3 (660
μL of 1 M solution in CH2Cl2, 660 μmol) was added slowly along the
ﬂask wall. After the solution was stirred for 1.5 h, DIPEA (300 μL, 1.73
mmol) was added to the ﬂask, followed by MeOH (2 mL) to quench
the reaction. The reaction was then warmed to room temperature, and
the solvents were removed under reduced pressure. The resulting
white solid was dissolved in 5:3 MeOH/1,4-dioxane and puriﬁed by
preparative HPLC (33% B for 5 min and 33−60% B over 20 min, 10
mL/min). The product eluted at 17 min and was lyophilized to yield
compound 4 as white solid (13.9 mg, 28%). 1H NMR (DMSO-d6, 500
MHz): δ 3.35−3.57 (16H, m), 4.38−4.41 (3H, m), 4.63−4.69 (3H,
m), 4.89−4.96 (3H, m), 6.74 (2H, dd, J = 7.5, 8.0 Hz), 6.97 (2H, d, J =
7.5 Hz), 7.35 (2H, d, J = 8.0 Hz), 7.46 (1H, s), 7.94 (1H, s), 8.33−
8.35 (1H, m), 9.12 (2H, d, J = 6.0 Hz), 9.29 (1H, d, J = 6.0 Hz), 9.44
(2H, bs), 9.76 (1H, bs), 11.6 (2H, bs), 11.9 (1H, bs). 13C NMR
(CDCl3, 125 MHz): δ 50.1, 51.5, 63.6, 69.1, 69.4, 69.8, 69.8, 69.9,
69.9, 115.3, 115.4, 115.4, 117.7, 118.5, 118.7, 119.4, 125.2, 145.9,
146.3, 148.7, 148.7, 150.8, 166.0, 168.4, 169.1, 169.6, 169.7. IR (KBr
disk, cm−1): 3389, 2954, 2928, 2868, 2111, 1754, 1645, 1589, 1535,
1460, 1384, 1329, 1266, 1176, 1132, 1074, 992, 846. HRMS (ESI): [M
+Na]+ m/z calcd 932.2506, found 932.2520.
Figure 1. Structures of enterobactin (1, Ent) and a generalized
enterobactin−cargo conjugate.
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N1-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-4,5-bis-
(benzyloxy)-N3-((3R,7R,11R)-7,11-bis(2,3-bis(benzyloxy)-
benzamido)-2,6,10-trioxo-1,5,9-trioxacyclododecan-3-yl)-
isophthalamide (5). 11-Azido-3,6,9-trioxaundecan-1-amine (36 μL,
181 μmol) and D-Bn6Ent-COOH (2, 177 mg, 142 μmol) were
dissolved in 5 mL of dry CH2Cl2. PyAOP (147 mg, 283 μmol) and
DIPEA (98.5 μL, 568 μmol) were added to give a light yellow
solution. The reaction was stirred for 4 h at room temperature and
concentrated, and the crude product was puriﬁed by preparative TLC
(50% EtOAc/CH2Cl2) to aﬀord 5 as white foam (159 mg, 77%). TLC
Rf = 0.6 (10% MeOH/CH2Cl2).
1H NMR (DMSO-d6, 500 MHz): δ
3.33 (2H, J = 5.2 Hz), 3.62−3.69 (14H, m), 4.02−4.06 (3H, m),
4.15−4.18 (3H, m), 4.91−4.94 (3H, m), 5.04−5.21 (12H, m), 6.96
(1H, s), 7.11−7.45 (36H, m), 7.65−7.67 (2H, m), 7.85−7.85 (1H, m),
7.97−7.97 (1H, m), 8.50−8.54 (3H, m). 13C NMR (CDCl3, 125
MHz): δ 25.6, 29.5, 38.8, 40.0, 45.3, 51.3, 51.4, 63.9, 64.1, 69.8, 39.8,
70.0, 70.3, 70.4, 70.4, 71.2, 71.2, 76.3, 76.3, 116.8, 117.5, 120.4, 123.0,
124.3, 125.4, 126.1, 126.2, 127.6, 127.6, 127.9, 128.2, 128.3, 128.4,
128.4, 128.5, 128.5, 128.6, 128.6, 128.8, 128.8, 128.9, 129.0, 130.1,
135.4, 135.7, 135.9, 136.0, 136.1, 146.8, 146.9, 149.1, 151.6, 151.8,
164.3, 164.9, 164.9, 165.8, 168.9, 169.0, 169.1, 176.2. IR (KBr disk,
cm−1): 3357, 3062, 3032, 2958, 2923, 2859, 2104, 1751, 1551, 1576,
1515, 1455, 1375, 1345, 1299, 1264, 1204, 1126, 1082, 1040, 1018,
957, 915, 854, 811. HRMS (ESI): [M+H]+ m/z calcd 1476.5323,
found 1476.5318.
N1-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethyl)-N3-
((3R,7R,11R)-7,11-bis(2,3-dihydroxybenzamido)-2,6,10-trioxo-
1,5,9-trioxacyclododecan-3-yl)-4,5-dihydroxyisophthalamide
(6). Compound 6 was synthesized from 5 (153 mg, 105 μmol)
following the same procedure as for compound 4. The crude reaction
was puriﬁed by preparative HPLC (33% B for 5 min and 33−60% B
over 20 min, 10 mL/min). The product eluted at 17.0 min and was
lyophilized to yield compound 6 as white solid (31 mg, 33%). 1H
NMR (CDCl3, 500 MHz): δ 3.34−3.56 (16H, m), 4.39−4.41 (3H,
m), 4.61−4.66 (3H, m), 4.88−4.94 (3H, m), 6.74 (2H, dd, J = 7.8, 7.8
Hz), 6.96 (2H, d, J = 7.8 Hz), 7.33 (2H, d, J = 7.8 Hz), 7.44 (1H, s),
7.91 (1H, s), 8.31−8.33 (1H, m), 9.12−9.13 (2H, m), 9.27−9.28 (1H,
m), 9.50 (2H, bs), 9.84 (1H, bs), 11.6 (2H, bs), 11.9 (1H, bs). 13C
NMR (CDCl3, 125 MHz): δ 50.1, 51.5, 63.6, 69.1, 69.4, 69.8, 69.8,
69.9, 69.9, 115.3, 115.4, 115.4, 117.7, 118.5, 118.7, 119.4, 125.2, 145.9,
146.3, 148.7, 148.7, 150.8, 166.0, 168.4, 169.1, 169.6, 169.7. IR (KBr
disk, cm−1): 3390, 2958, 2925, 2863, 2110, 1754, 1645, 1589, 1535,
1460, 1384, 1342, 1262, 1176, 1117, 1074, 841, 800. HRMS (ESI): [M
+Na]+ m/z calcd 936.2506, found 936.2512.
(2S,5R,6R)-6-((R)-2-(Hex-5-ynamido)-2-phenylacetamido)-
3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carb-
oxylic Acid (7). 5-Hexynoic acid (113 μL, 1.00 mmol) and thionyl
chloride (1.00 mL, 13.8 mmol) were combined and reﬂuxed for 1 h.
The reaction was cooled to room temperature and concentrated under
reduced pressure, and the resulting crude acyl chloride was dissolved
in acetone (0.5 mL) and carried on to the next step without
puriﬁcation. Ampicillin sodium salt (186 mg, 0.500 mmol) was
dissolved in a solution of NaHCO3 (210 mg, 2.5 mmol) in 4:1 water/
acetone (2.5 mL) and cooled on ice, to which the acyl chloride was
added slowly with stirring. The reaction was subsequently warmed to
room temperature and stirred for 1 h. Water (3 mL) was added to the
reaction, and the aqueous phase was washed with EtOAc (2 × 10 mL),
acidiﬁed to pH 2 by addition of HCl, and extracted with EtOAc (20
mL). The resulting organic phase was washed with cold water (2 × 5
mL), dried over Na2SO4, and concentrated under reduced pressure.
The crude reaction was triturated with hexanes, which aﬀorded a
yellow solid (180 mg, 77%). This solid was used in the following steps
without further puriﬁcation. TLC Rf = 0.1 (10% MeOH/CH2Cl2).
1H
NMR (DMSO-d6, 500 MHz): δ 1.41 (3H, s), 1.55 (3H, s), 1.64−1.69
(2H, m), 2.13−2.16 (2H, m), 2.29−2.32 (2H, m), 2.77−2.78 (1H, m),
4.20 (1H, s), 5.39 (1H, d, J = 4.0 Hz), 5.52 (1H, dd, J = 4.0, 8.0 Hz),
5.70 (1H, d, J = 8.0 Hz), 7.25−7.43 (5H, m), 8.57 (1H, d, J = 8.0 Hz),
9.11 (1H, d, J = 8.0 Hz). 13C NMR (DMSO-d6, 125 MHz): δ 17.4,
24.4, 26.6, 30.4, 33.8, 55.5, 58.1, 63.7, 67.3, 70.3, 71.5, 84.2, 127.2,
127.6, 128.2, 138.2, 169.0, 170.2, 171.5, 173.5. IR (KBr disk, cm−1):
3297, 3058, 3023, 2970, 2937, 2863, 2626, 2526, 2120, 1780, 1688,
1518,1455, 1437, 1390, 1373, 1324, 1295, 1208, 1139, 1027, 1001,
843. HRMS (ESI): [M+H]+ m/z calcd 444.1588, found 444.1585.
(2S,5R,6R)-6-((R)-2-(Hex-5-ynamido)-2-(4-hydroxyphenyl)-
acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]-
heptane-2-carboxylic Acid (8). Compound 8 was synthesized as
described for compound 7 except that amoxicillin (760 mg, 2.1 mmol)
was used instead of ampicillin sodium salt. Compound 8 was obtained
as light yellow solid (533 mg, 56%) after trituration and employed
without further puriﬁcation. TLC Rf = 0.1 (10% MeOH/CH2Cl2).
1H
NMR (DMSO-d6, 500 MHz): δ 1.42 (3H, s), 1.56 (3H, s), 1.63−1.68
(2H, m), 2.12−2.15 (2H, m), 2.25−2.29 (2H, m), 2.76−2.78 (1H, m),
4.19 (1H, s), 5.39 (1H, d, J = 4.0 Hz), 5.51−5.54 (2H, m), 6.69 (2H,
d, J = 8.5 Hz), 7.19 (2H, d, J = 8.5 Hz), 8.41 (1H, d, J = 8.0 Hz), 8.93
(1H, d, J = 8.0 Hz), 9.40 (1H, bs). 13C NMR (DMSO-d6, 125 MHz):
δ 17.6, 24.5, 26.8, 30.4, 34.0, 55.4, 58.2, 63.9, 71.6, 71.7, 84.4, 115.1,
128.4, 128.7, 128.8, 157.0, 169.2, 170.9, 171.7, 173.8. IR (KBr disk,
cm−1): 3356, 3294, 3045, 2970, 2928, 1770, 1738, 1650, 1615, 1515,
1457, 1373, 1208, 1009, 945, 839, 815. HRMS (ESI): [M+Na]+ m/z
calcd 460.1537, found 460.1534.
(4S)-2-(((R)-2-(Hex-5-ynamido)-2-phenylacetamido)methyl)-
5,5-dimethylthiazolidine-4-carboxylic Acid (9). Compound 7 (60
mg, 0.13 mmol) was dissolved in 1:1 H2O/MeCN (5 mL), and TFA
was added to a ﬁnal concentration of 1%. The solution was incubated
at 37 °C for 24 h and puriﬁed by preparative HPLC (20−50% B over
25 min, 10 mL/min), which aﬀorded a white powder (12 mg, 25%).
The white powder is a diastereomeric mixture of products, and no
further separation was performed. 1H NMR (DMSO-d6, 500 MHz): δ
(mixture of two diastereomers) 1.22−1.23 (3H, pair of s), 1.54−1.58
(3H, pair of s), 1.62−1.68 (2H, m), 2.12−2.14 (2H, m), 2.28−2.30
(2H, m), 2.77 (1H, s), 3.18−3.24 (0.5H, m), 3.30−3.36 (0.5H, m),
3.44−3.49 (0.5H, m), 3.55−3.60 (0.5H, m), 3.92 (0.5H, s), 4.01
(0.5H, s), 4.67 (0.5H, dd, J = 6.7, 6.5 Hz), 4.78 (0.5H, dd, J = 5.2, 5.2
Hz), 5.45−5.48 (1H, m), 7.27−7.40 (5H, m), 8.50−8.61 (2H, m). 13C
NMR (DMSO-d6, 125 MHz): δ (mixture of two diastereomers) 18.1,
25.0, 27.6, 28.1, 28.4, 29.5, 34.4, 42.2, 56.8, 56.8, 72.1, 72.2, 84.8,
127.9, 128.2, 128.9, 139.2, 139.4, 171.2, 171.4, 172.0. IR (KBr disk,
cm−1): 3297, 3071, 3041, 2967, 2938, 2535, 2124, 1734, 1653, 1527,
1456, 1427, 1375, 1299, 1199, 1137, 1070, 1027, 836. HRMS (ESI):
[M+Na]+ m/z calcd 440.1614, found 440.1626.
(4S)-2-(((R)-2-(Hex-5-ynamido)-2-(4-hydroxyphenyl)-
acetamido)methyl)-5,5-dimethylthiazolidine-4-carboxylic Acid
(10). Compound 10 was synthesized as described for compound 9
except that compound 8 was used instead of 7 (60 mg, 0.13 mmol).
The product was puriﬁed by preparative HPLC (20−50% B over 25
min, 10 mL/min), and obtained as white powder (14.5 mg, 24%). 1H
NMR (DMSO-d6, 500 MHz): δ (mixture of two diastereomers) 1.26
(3H, s), 1.55−1.59 (3H, pair of s), 1.61−1.67 (2H, m), 2.12−2.14
(2H, m), 2.24−2.27 (2H, m), 2.77 (1H, s), 3.20−3.26 (0.5H, m),
3.34−3.39 (0.5H, m), 3.42−3.47 (0.5H, m), 3.56−3.60 (0.5H, m),
4.03 (0.5H, s), 4.12 (0.5H, s), 4.68 (0.5H, dd, J = 6.5, 6.5 Hz), 4.79
(0.5H, dd, J = 5.5, 5.5 Hz), 5.28−5.31 (1H, m), 6.69 (2H, d, J = 8.5
Hz), 7.17 (2H, d, J = 8.5 Hz), 8.36−8.50 (3H, m). 13C NMR (DMSO-
d6, 125 MHz): δ (mixture of two diastereomers) 17.5, 24.3, 26.9, 27.5,
27.7, 28.8, 33.8, 41.4, 55.7, 55.8, 71.4, 71.6, 84.2, 114.8, 115.0, 128.5,
128.7, 128.8, 156.9, 158.3, 158.6, 171.2, 171.3. IR (KBr disk, cm−1):
3301, 3071, 3028, 2973, 2928, 2548, 2111, 1737, 1662, 1606, 1593,
1515, 1435, 1377, 1197, 1139, 837. HRMS (ESI): [M+Na]+ m/z calcd
456.1564, found 456.1569.
Ent-Amp (11). Ampicillin-alkyne 7 (120 μL of an 80 mM solution
in DMSO, 9.6 μmol) and Ent-PEG3-N3 4 (250 μL of a 13 mM
solution in 1,4-dioxane, 3.3 μmol) were combined, and 400 μL of
DMSO was added. CuSO4 (100 μL of a 90 mM solution in water, 9.0
μmol) and tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA,
200 μL of a 50 mM solution in DMSO, 10 μmol) were combined, and
100 μL of DMSO was added to give a blue-green solution, to which
NaAsc (400 μL of a 90 mM solution in water, 36.0 μmol) was added.
This solution became light yellow and was immediately added to the
alkyne/azide solution. The reaction was shaken on a benchtop rotator
for 2 h at room temperature, diluted by 3- to 4-fold with 1:1 MeCN/
water, centrifuged (13,000 rpm × 10 min, 4 °C), and puriﬁed by semi-
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preparative HPLC (20% B for 5 min and 20%−50% B over 11 min, 4
mL/min; 0.005% TFA was used in the solvent system to prevent
decomposition of the β-lactam). The HPLC fractions containing 11
were collected manually and ﬂash frozen in liquid N2 immediately after
collection to prevent β-lactam decomposition. The product was
obtained as white powder (3.3 mg, 76%). 1H NMR (DMSO-d6, 500
MHz): δ 1.40 (3H, s), 1.54 (3H, s), 1.78−1.81 (2H, m), 2.27 (2H, t, J
= 6.8 Hz), 2.58 (2H, t, J = 6.5 Hz), 3.48 (12H, m), 3.76 (2H, s), 4.19
(1H, s), 4.38−4.44 (5H, m), 4.64−4.66 (3H, m), 4.91−4.92 (3H, m),
5.39 (1H, d, J = 3.5 Hz), 5.51−5.52 (1H, m), 5.72 (1H, d, J = 7.5 Hz),
6.74 (2H, dd, J = 7.8, 7.8 Hz), 6.96 (2H, d, J = 7.5 Hz), 7.26−7.35
(5H, m), 7.42−7.45 (3H, m), 7.81 (1H, s), 7.92 (1H, s), 8.33 (1H, s),
8.55 (1H, d, J = 7.5 Hz), 9.12 (3H, d, J = 7.0 Hz), 9.29 (1H, d, J = 6.5
Hz), 9.42 (2H, bs), 9.74 (1H, s), 11.6 (2H, s), 11.9 (1H, bs), 13.35
(1H, bs). HRMS (ESI): [M+Na]+ m/z calcd 1379.4021, found
1379.4046.
Ent-Amx (12). Compound 12 was synthesized as described for 11
except that compound 8 was used instead of compound 7. The
product was obtained as white powder (2.9 mg, 66%). 1H NMR
(DMSO-d6, 500 MHz): δ 1.40 (3H, s), 1.54 (3H, s), 1.78−1.80 (2H,
m), 2.23 (2H, t, J = 6.5 Hz), 2.57 (2H, t, J = 6.5 Hz), 3.47 (12H, m),
3.76 (2H, bs), 4.18 (1H, s), 4.39−4.43 (5H, m), 4.63−4.65 (3H, m),
4.90 (3H, bs), 5.38 (1H, s), 5.52−5.56 (2H, m), 6.68 (2H, d, J = 8.5
Hz), 6.73 (2H, dd, J = 7.8, 7.8 Hz), 6.96 (2H, d, J = 7.5), 7.19 (2H, d, J
= 8.5 Hz), 7.33 (2H, d, J = 7.5 Hz), 7.44 (1H, s), 7.80 (1H, s), 7.92
(1H, s), 8.33−8.39 (2H, m), 8.94 (1H, d, J = 8.0 Hz), 9.11−9.12 (2H,
m), 9.29 (1H, bs), 9.38−9.43 (3H, m), 9.75 (1H, s), 11.6 (2H, bs),
11.9 (1H, bs). HRMS (ESI): [M+Na]+ m/z calcd 1395.3970, found
1395.3982.
D-Ent-Amp (13). Compound 13 was synthesized as described for
11 except that compound 6 was used instead of compound 4. The
product was obtained as white powder (1.6 mg, 36%). HRMS (ESI):
[M+Na]+ m/z calcd 1379.4021, found 1379.4022.
D-Ent-Amx (14). Compound 14 was synthesized as described for
12 except that compound 6 was used instead of compound 4. The
product was obtained as white powder (2.9 mg, 66%). HRMS (ESI):
[M+Na]+ m/z calcd 1395.3970, found 1395.3995.
Ent-Hydro-Amp (15). Compound 15 was synthesized as described
for 11 except that compound 9 was used instead of compound 7. The
product was obtained as white powder (1.8 mg, 21%). HRMS (ESI):
[M+H]+ m/z calcd 1331.4409, found 1331.4389.
Ent-Hydro-Amx (16). Compound 16 was synthesized as described
for 12 except that compound 10 was used instead of compound 8. The
product was obtained as white powder (1.5 mg, 17%). HRMS (ESI):
[M+Na]+ m/z calcd 1369.4177, found 1369.4191.
General Procedures for Antimicrobial Activity Assays.
General microbiology materials and methods, including details of
Ent-Amp/Amx stock solution preparation and storage, are provided as
Supporting Information. Overnight cultures of the bacterial strains
(Table S1) were prepared in 15-mL polypropylene tubes by
inoculating 5 mL of LB media with the appropriate freezer stock.
The overnight cultures were incubated at 37 °C for 16−18 h in a
tabletop incubator shaker set at 150 rpm and housing a beaker of
water. Each overnight culture was diluted 1:100 into 5 mL of fresh LB
media containing 200 μM 2,2′-dipyridyl (DP) and incubated at 37 °C
with shaking at 150 rpm until OD600 reached 0.6. Each culture was
subsequently diluted in 50% MHB medium (10.5 g/L) with or
without 200 μM DP to achieve an OD600 value of 0.001. A 90-μL
aliquot of the diluted culture was combined with a 10-μL aliquot of a
10× solution of the antibiotic or Ent-antibiotic conjugate in a 96-well
plate, and the covered plate was wrapped in paraﬁlm and incubated at
30 °C with shaking at 150 rpm for 19 h in a tabletop incubator
housing a beaker of water. Bacterial growth was determined by
measuring OD600 (end point analysis) using a BioTek Synergy HT
plate reader. Each well condition was prepared in duplicate and at least
three independent replicates using two diﬀerent synthetic batches of
each conjugate were conducted on diﬀerent days. The resulting mean
OD600 values are reported, and the error bars are the standard error of
the mean (SEM) obtained from the independent replicates.
Antimicrobial Assays in the Presence of β-Lactamase
Inhibitors. These assays were performed with E. coli ATCC 35218
and K. pneumoniae ATCC 13883 following the general procedure
except that sulbactam (SB) or potassium clavulanate (PC) were mixed
with ampicillin or amoxicillin and the Ent-Amp or Ent-Amx
conjugates, respectively. The molar ratios of the inhibitor/β-lactam
mixtures were sulbactam/Amp or Ent-Amp, 1.5:1, and potassium
clavulanate/Amx or Ent-Amx, 0.9:1. These ratios were taken from the
recipe of commercial drug combinations.68 SB and PC were stored as
DMSO stock solutions at −20 °C.
Antimicrobial Assays in the Presence of Exogenous Ent.
These assays were performed with E. coli K-12 and CFT073 following
the general procedure except that varying concentrations (1−100 μM)
of synthetic L-Ent were mixed with Ent-Amp/Amx.
Antimicrobial Activity Assays in the Presence of Lipocalin 2.
This assay is based on a published protocol69 and was conducted with
E. coli CFT073. Overnight cultures of E. coli CFT073 were grown in
M9 minimal medium. Each overnight culture was serially diluted into
M9 minimal medium to provide 103−104 CFU/mL. Lipocalin 2 was
diluted in PBS to a concentration of 10 μM upon arrival, aliquoted,
and stored at −20 °C until use. A 90-μL aliquot of the diluted culture
was added to each well of a 96-well plate that contained varying
concentrations of lipocalin 2, Ent-Amp, and Ent, and the ﬁnal volume
was adjusted to 100 μL with sterile PBS. The 96-well plate was
incubated at 37 °C for 24 h in a tabletop incubator set at 150 rpm, and
bacterial growth was determined by measuring OD600 using a plate
reader. Each well condition was repeated at least three times
independently on diﬀerent days and with diﬀerent batches of lipocalin
2. The resulting mean OD600 is reported, and the error bars are the
SEM.
Time-Kill Kinetic Assays. A 5-mL overnight culture of E. coli K-12
or CFT073 was grown in LB (vide supra) and diluted 1:100 into 5 mL
of fresh LB media containing 200 μM DP, and this culture was
incubated at 37 °C with shaking at 150 rpm in a tabletop incubator
housing a beaker of water until OD600 reached ∼0.3. The culture was
centrifuged (3000 rpm × 10 min, rt), and the resulting pellet was
washed twice by resuspension in 50% MHB and centrifugation (3000
rpm × 10 min, rt). The resulting pellet was resuspended in 50% MHB
with or without DP, and the OD600 was adjusted to 0.3. A 90-μL
aliquot of the resulting culture was mixed with a 10-μL aliquot of a
10× solution of Amp/Amx or the Ent-Amp/Amx in a 96-well plate,
which was covered, wrapped in paraﬁlm, and incubated at 37 °C with
shaking at 150 rpm. The OD600 values were recorded at t = 0, 1, 2, and
3 h by using a plate reader. In a parallel experiment, a 10-μL aliquot of
the culture was taken at t = 0, 1, 2, and 3 h, serially diluted by using
sterile phosphate-buﬀered saline (PBS), and plated on LB-Agar plates
for colony counting (CFU/mL). Each well condition was repeated at
least three times independently on diﬀerent days. The resulting mean
OD600 or CFU/mL is reported, and the error bars are the SEM.
Mixed-Species Assays. A 5 mL overnight culture of each bacterial
strain was grown in LB, diluted 1:100 into 5 mL of fresh LB media
containing 200 μM DP, and incubated at 37 °C with shaking at 150
rpm in a tabletop incubator housing a beaker of water until OD600
reached 0.6. Each mid-log-phase culture was diluted to 106 CFU/mL
in 50% MHB with or without 200 μM DP. For experiments requiring a
mixture of two species, a 1:1 mixture was prepared (106 CFU/mL for
each strain) in 50% MHB with or without 200 μM DP from the mid-
log-phase cultures. To conﬁrm CFU/mL of each culture, the single-
and double-species cultures were serially diluted by using sterile PBS,
and aliquots were plated on a CHROM-UTI plate (“starter-culture
plate”). For each cell-killing experiment, a 90-μL aliquot of each
culture was combined with a 10-μL aliquot of a 10 μM solution of the
antibiotic or Ent-antibiotic conjugate in a 96-well plate, which was
covered, wrapped in paraﬁlm, and incubated at 30 °C with shaking at
150 rpm for 19 h. Bacterial growth was assayed both by measuring
OD600 using the plate reader and by plating on CHROM-UTI plates
after serial dilution (“assay plate”). Each well condition was repeated at
least three times independently on diﬀerent days. The resulting mean
OD600 is reported, and the error bars are the SEM. Images of
representative CHROM-UTI plates are presented.
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■ RESULTS AND DISCUSSION
Design and Syntheses of Enterobactin−Antibiotic
Conjugates Harboring β-Lactams. We aimed to harness
our enterobactin-mediated cargo delivery strategy to enable the
transport of toxic cargo across the outer membrane of E. coli.
To address this goal, we linked the β-lactam antibiotics
ampicillin (Amp) and amoxicillin (Amx) to a monofunction-
alized Ent scaﬀold where Ent is derivatized at the C5 position
of one catechol ring via a ﬂexible and stable PEG3 linker. We
selected Amp and Amx as antibacterial cargo for several
reasons: these molecules are commercially available and
amenable to synthetic modiﬁcation, retain antibacterial activity
when appropriately modiﬁed, possess periplasmic targets in
Gram-negative bacteria and must cross the outer membrane to
be active against these species, and have relatively low
molecular weights. We selected low-molecular-weight anti-
biotics because our prior studies of Ent-mediated cargo
transport indicated that the Ent transport machinery of E. coli
K-12 imports Ent-cargo conjugates harboring relatively small
cargos (e.g., cyclohexane, naphthalene, phenylmethylbenzene)
to the cytosol readily, whereas large cargos (e.g., vancomycin)
are not transported to the cytosol.66 Moreover, in prior studies,
various β-lactams including Amp and Amx have been linked
to simple catechols29−32,34−40 and more complex catechol-
containing siderophores or mimics thereof,43,44,49,50,53,56,70
which provides the opportunity to compare the outcomes
obtained for diﬀerent siderophore-inspired design strategies.
In Scheme 1, we present the syntheses of Ent-Amp 11 and
Ent-Amx 12, which feature installation of alkyne-modiﬁed β-
lactam warheads onto Ent-azide 4 via copper-catalyzed azide-
alkyne cycloaddition (hereafter click reaction) in the ﬁnal step.
The catechol moieties of benzyl-protected Ent-azide 3 were
deprotected by using BCl3 at −78 °C to achieve Ent-azide 4 as
a white powder in 28% yield following puriﬁcation by reverse-
phase preparative HPLC. Catalytic hydrogenation using
hydrogen gas and a Pd/C catalyst is typically employed to
deprotect Ent catechols;67,71 however, we observed that Amp/
Amx decompose under these conditions and poison the Pd/C
catalyst. Moreover, deprotection of the enterobactin catechols
prior to installing the β-lactams requires preservation of the
azide moiety, and we therefore employed BCl3 for this reaction.
Initial attempts at assembling Ent-Amp/Amx using standard
conditions for the copper-catalyzed click reactions with Ent-
azide 4 and the alkyne-modiﬁed β-lactams 7/8, prepared by
thionyl chloride coupling of 5-hexynoic acid to the amino group
of Amp/Amx, failed because of copper-mediated β-lactam
decomposition.72 This problem was overcome by including the
metal-ion chelator tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-
amine (TBTA)73 in the click reactions, and Ent-Amp and Ent-
Amx were obtained as white powders in high purity and yields
of 66% and 76%, respectively, following semi-preparative
HPLC puriﬁcation. It was necessary to perform HPLC
puriﬁcation with eluents containing only 0.005% TFA to
prevent decomposition of the acid-sensitive β-lactam moieties.
This synthetic route was likewise employed to prepare the D-
enantiomers of Ent-Amp/Amx 13 and 14 (Scheme 1).
This synthesis aﬀords intermediates and reaction conditions
of broad utility. Deprotected Ent-azide 4 enables alkyne-
functionalized molecules to be covalently linked to Ent via a
click reaction, including molecules that are incompatible with
reaction conditions required to deprotect the Ent catechols.
Moreover, the deprotected Ent-azide may be employed to
append Ent to surfaces, other materials, or biomolecules
harboring alkyne groups. This synthesis also provides
opportunity to elaborate β-lactams for a variety of purposes.
Indeed, very few examples employing the copper(I)-catalyzed
click reaction with fused β-lactams are reported in the
literature,74,75 and it is likely that this paucity stems from the
fact that β-lactams are incompatible with standard conditions
for copper-catalyzed azide-alkyne cycloaddition.72 The con-
ditions deﬁned in this work employing TBTA allow for copper-
catalyzed triazole formation and preserve the β-lactam warhead.
Ent-Amp/Amx Coordinate Fe(III). In the absence of
Fe(III), Ent-Amp/Amx exhibit an absorption band centered at
316 nm resulting from catecholate absorption and the solutions
are colorless (MeOH, rt). Addition of 1.0 equiv of Fe(III) to
methanolic solutions of Ent-Amp and Ent-Amx causes the
solution to immediately change from colorless to purple-red,
and a broad absorption feature in the 400−700 nm range
appears (Figure S1), conﬁrming that both Ent-Amp/Amx
readily chelate Fe(III).
Ent-Amp/Amx Exhibit Enhanced Antibacterial Activ-
ity against Various E. coli Strains Including Human
Pathogens. To ascertain whether Ent-Amp/Amx provide
antibacterial activity against E. coli, including pathogenic
strains,76 we preformed antimicrobial activity assays using six
Scheme 1. Syntheses of the L and D Forms of Ent-Amp/Amx
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strains (Table S1, Figures 2, S2−S7). E. coli ATCC 25922 is a
laboratory susceptibility test strain originally obtained as a
clinical isolate. E. coli H9049 is a non-pathogenic clinical
isolate.77 E. coli UTI8978 and CFT07379 are both pathogens of
the human urinary tract (UPEC).80 E. coli ATCC 35401
(serotype O78:H11) is an enterotoxigenic (ETEC) strain that
was isolated from human feces. E. coli ATCC 43895 (serotype
O157:H7) is an enterohemorrhagic (EHEC) strain that was
isolated from raw hamburger meat implicated in a hemorrhagic
colitis outbreak. Both ETEC and EHEC strains produce
virulence factors and toxins and cause diarrhea in humans.76 All
E. coli strains biosynthesize Ent for iron acquisition and express
the Ent receptor FepA. Some E. coli strains employed in this
work also have the capacity to produce and utilize salmochelins,
C-glucoyslated Ent derivatives.81 These molecules are produced
by Salmonella spp. and pathogenic E. coli strains for iron
acquisition. The iroA gene cluster (iroBCDEN) encodes
proteins required for the biosynthesis and transport of
salmochelins, and IroN is the outer membrane receptor for
salmochelins encoded by the iroA cluster.82,83 Studies with
Salmonella indicate that IroN has the ability to transport Ent as
well as its glucosylated forms.84 Of the strains considered in this
work, E. coli CFT073 and UTI89 harbor the iroA gene cluster.
E. coli H9049 does not produce salmochelins,85 and a BLAST
search using available E. coli genomes reveals that the E. coli
43985 genome does not contain the iroA cluster. The genome
for E. coli ATCC 25922 is unpublished; however, this strain is
reported to be sensitive to lipocalin-2 (vide inf ra),86 which
suggests that its genome does not encode the iroA cluster.
Whether E. coli 35401 produces salmochelins is unclear from
the available literature. Lastly, it should be noted that E. coli
CFT073 is celebrated for having redundant iron import
machineries, and this strain also harbors the iha gene, which
encodes the outer membrane Ent receptor Iha that is distinct
from FepA.87
We performed antibacterial activity assays using a 10-fold
dilution series to compare the abilities of Ent-Amp/Amx and
unmodiﬁed Amp/Amx to kill E. coli (Figures 2, S2−S7). These
assays were conducted in 50% MHB and in the absence or
presence of 200 μM DP. The latter growth conditions provide
iron limitation and result in expression of the Ent uptake
machinery FepABCDG. Amp/Amx exhibit minimum inhibitory
concentration (MIC) values of 10 μM against these E. coli
strains regardless of the presence of DP in the growth medium
(Figures 2, S2−S7). All six E. coli strains are more susceptible to
Ent-Amp/Amx than Amp/Amx under conditions of iron
limitation (Figure 2). Based on the 10-fold dilution series,
Ent-Amp/Amx are 100-fold more potent against E. coli 25922,
UTI89, and H9049 under iron-limiting conditions. Although
the MIC values for 35401 and 43895 are only ca. 10-fold higher
than for Amp/Amx in this assay, a signiﬁcant reduction in
growth is observed at 100 nM Ent-Amp/Amx, whereas this
concentration of Amp/Amx aﬀords no growth inhibition. The
enhanced sensitivity of E. coli CFT073 to Ent-Amp/Amx is
Figure 2. Antibacterial activity of Ent-Amp/Amx against various E. coli strains that include human pathogens. (A) Laboratory test strain E. coli
ATCC 25922. (B) Uropathogenic E. coli UTI89. (C) Uropathogenic E. coli CFT073. (D) Non-pathogenic clinical isolate E. coli H9049. (E)
Pathogenic ETEC E. coli ATCC 35401. (F) Pathogenic EHEC E. coli ATCC 43895. All assays were performed in 50% MHB medium supplemented
with 200 μM DP to provide iron-limiting conditions (mean ± SEM, n ≥ 3). The data for assays performed in the absence of DP are presented in
Figures S2−S7.
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remarkable. This strain exhibits the greatest sensitivity to Ent-
Amp/Amx, providing a 1000-fold decreased MIC value (10
nM), and growth inhibition in the presence of ≤1 nM of the
conjugate. Moreover, in the absence of DP, E. coli CFT073
exhibits the greatest susceptibility to Ent-Amp/Amx (Figures
S2−S7). A noteworthy characteristic of CFT073 is its multiple
mechanisms for iron acquisition, and we hypothesize that the
presence of multiple receptors that recognize and transport Ent
(FepA, IroN, Iha) contributes to this enhanced sensitivity.
CFT073 and UTI89 both express IroN, which may indicate
that Iha is responsible for the enhanced susceptibility of
CFT073; however, we cannot rule out the possibility that the
conserved receptors function diﬀerently or exhibit diﬀerent
expression levels depending on the strain. Moreover, other
unappreciated mechanisms may contribute to the potent
bactericidal action exhibited by Ent-Amp/Amx against
CFT073 and other strains.
Ent-Amp/Amx Exhibit Enhanced Antimicrobial Activ-
ity against E. coli K-12. To gain further insight into the
mechanism of Ent-Amp/Amx antibacterial action, we per-
formed a series of experiments with the standard laboratory
strain E. coli K-12. We employed the same 10-fold dilution
series to compare the activities of Ent-Amp/Amx and Amp/
Amx against K-12. In the absence of DP, Ent-Amp/Amx and
Amp/Amx exhibit comparable MIC values, with complete
killing observed at ∼10 μM. At lower concentrations, Ent-
Amp/Amx exhibit slightly greater antibacterial activity than
unmodiﬁed Amp/Amx (Figure 3A). This phenomenon is most
evident at a conjugate/drug concentration of 1 μM, where Ent-
Amp/Amx inhibit E. coli K-12 growth to varying degrees and
Amp/Amx do not aﬀect bacterial growth. Under conditions of
Figure 3. Antibacterial activity of Ent-Amp/Amx against wild-type and mutant E. coli K-12. (A,B) Growth inhibition of E. coli K-12 by Amp/Amx
and Ent-Amp/Amx in the absence (A) and presence (B) of DP. (C) Growth inhibition of E. coli K-12 treated with a 1:1 molar ratio of Ent/Amp and
Ent/Amx. (D) Growth inhibition of E. coli K-12 treated with ferric Ent-Amp/Amx. (E−G) Growth inhibition of fepA- (E), fepC- (F), and fes- (G) by
Amp/Amx and Ent-Amp/Amx. (H,I) Growth of E. coli K-12 in the presence of 1 μM Ent-Amp/Amx (“conjugate”) and mixtures of Ent-Amp/Amx
(1 μM) and 1, 5, or 20 equiv of exogenous Ent in the absence (H) and presence (I) of DP. The ** indicates OD600 < 0.01. All assays were performed
in 50% MHB medium with or without 200 μM DP (see panels) (mean ± SEM, n ≥ 3). The data for additional assays performed in the absence of
DP are presented in Figure S8.
Journal of the American Chemical Society Article
dx.doi.org/10.1021/ja503911p | J. Am. Chem. Soc. 2014, 136, 9677−96919683
iron limitation, a 100-fold reduction in MIC value (10 μM to
100 nM) for Ent-Amp/Amx is observed, and ca. 50% growth
inhibition occurs at 10 nM of each conjugate (Figure 3B).
These trends are comparable to those observed for E. coli
ATCC 25922, H9049, and UTI89 (Figures 2, S2, S3, and S5).
When the antibacterial activity assay was performed using a 1:1
ratio of native L-Ent and Amp/Amx, no reduction of Amp/Amx
MIC values was observed (Figure 3C), which suggests the
conjugation between Ent and the β-lactams is required for the
enhanced bactericidal action. Moreover, treatment of E. coli K-
12 with the iron-bound forms of Ent-Amp/Amx, obtained by
pre-incubating each conjugate with 1 equiv of ferric chloride,
aﬀorded the same MIC values as observed for apo Ent-Amp/
Amx. These results indicate that the enhanced antibacterial
activity does not result from iron chelation in the growth media
(Figure 3D). In total, the data obtained for E. coli K-12 as well
as the six other E. coli strains demonstrate that the antibacterial
activity of Ent-Amp/Amx against E. coli K-12 is enhanced under
conditions of iron limitation and support a model of Ent-
mediated delivery of antibacterial cargo to the E. coli periplasm.
FepA Is Essential for Ent-Amp/Amx Antimicrobial
Activity against E. coli K-12. To evaluate transport of Ent-
Amp/Amx into E. coli, we investigated the antimicrobial activity
of Ent-Amp/Amx and Amp/Amx against three single-gene
knockout E. coli K-12 strains obtained from the Keio
Collection,88 fepA-, fepC-, and fes- (Figures 3E−G and S8).
We selected these mutants to ascertain how components of the
enterobactin transport and processing machinery contribute to
Ent-Amp/Amx antibacterial activity. E. coli fepA- lacks the outer
membrane Ent receptor FepA that allows periplasmic delivery,
fepC- lacks the ATPase component of the inner membrane Ent
permease that transports Ent into the cytosol, and E. coli fes-
lacks the cytoplasmic esterase Fes responsible for hydrolysis of
the Ent macrolactone for iron release. On the basis of our
studies with wild-type K-12 and other E. coli strains, we
hypothesized that the activity of Ent-Amp/Amx would be
attenuated for the fepA- mutant. Moreover, we questioned
whether loss of FepC or Fes would modulate the antimicrobial
activity.
Overnight cultures of fepA- and fepC- reached OD600 values
(∼0.15) similar to that observed for wild-type K-12 when
grown in 50% MHB supplemented with 200 μM DP. In
contrast, the fes- strain exhibited a severe growth defect under
these conditions (OD600 ≈ 0.04). Treatment of fepA- with Ent-
Amp/Amx aﬀorded the same MIC values as for Amp/Amx
(Figure 3E) and hence a 100-fold reduction in activity as
compared to wild-type K-12. Iron deprivation is deleterious to
E. coli, and we contend that the growth inhibition observed at
10 μM Ent-Amp/Amx results from iron starvation rather than
an antibacterial activity of the Amp/Amx cargo. Analysis of 50%
MHB by inductively coupled plasma optical emission spec-
troscopy (ICP-OES) revealed a total iron concentration of ca. 4
μM (Table S2), which can be compared to 10 μM of a high-
aﬃnity extracellular iron chelator. Indeed, we previously
observed similar growth inhibition of fepA- with 10 μM of an
Ent-vancomycin conjugate (extracellular iron chelation) and
also 10 μM D-Ent (iron chelator that cannot be used for iron
acquisition) under these growth conditions.66 These data
conﬁrm that FepA is essential for the potent antibacterial
activity of Ent-Amp/Amx against E. coli K-12.
In contrast to fepA-, the growth of fepC- and fes- was
completely inhibited with 100 nM Ent-Amp/Amx under iron-
limiting conditions (Figure 3F,G), comparable to what was
observed for the wild-type strain. The targets of β-lactam
antibiotics are penicillin binding proteins (PBPs), which are
located in the periplasm of Gram-negative bacteria. After
crossing the outer membrane through FepA, Ent-Amp/Amx
enter the periplasm where covalent capture by the PBPs
presumably occurs. Thus, it is reasonable that the downstream
Ent transport and processing steps involving FepCDG and Fes
do not aﬀect the antimicrobial activity of the conjugates if they
are trapped in the periplasm as a result of PBP binding.
Although it is possible that the Ent uptake machinery (e.g.,
periplasmic binding protein FepB) competes with the PBPs for
Ent-Amp/Amx, no improved antibacterial activities were
observed for the fepC- and fes- mutants compared to wild-
type K-12. This observation indicates that Ent-Amp/Amx bind
to PBPs and are trapped in the periplasm. It should be noted
that the fepB- mutant, which lacks the periplasmic binding
protein, was also considered in this work; however, this strain
exhibited a severe growth defect and aﬀorded inconsistent
results.
Ent-Amp/Amx and L-Ent Compete for FepA Recog-
nition. To probe interaction between FepA and Ent-Amp/
Amx, we performed growth inhibition assays employing
mixtures of Ent-Amp/Amx and varying concentrations of
unmodiﬁed Ent (Figure 3H−I). When these assays were
performed under conditions of iron limitation, the presence of
exogenous Ent attenuated the antibacterial activity of Ent-
Amp/Amx. A 1:1 molar ratio of Ent-Amx/Ent aﬀorded an
OD600 value comparable to that of the untreated control,
whereas higher equivalents of Ent were required to block the
antibacterial action of Ent-Amp. The origins of this diﬀerence
are unclear and may indicate that the hydroxyl group of Amx
has a negative eﬀect on the transport eﬃciency of the
conjugate. In total, these Ent addition assays suggest that
competition for Ent-Amp/Amx and Ent occurs at the
receptor(s) and that the conjugates are delivered into the
bacteria via the same uptake machinery as Ent.
Antibacterial Activity of D-Ent-Amp/Amx. L-Serine is a
biosynthetic building block for Ent, and a role for chiral
recognition in Ent transport has been probed in prior
studies.89,90 In one series of investigations, E. coli FepA was
found to bind ferric L-Ent and ferric D-Ent with similar aﬃnities
(Kd = 21 and 17 nM, respectively; ascertained by measuring the
binding of 59Fe-loaded siderophores to E. coli BN1071 cells).89
A lack of transport of ferric D-Ent into E. coli BN1071 was also
reported in this work. A later study probed Ent uptake in
Bacillus subtilis, and transport of both L- and D-Ent analogues
was observed to occur with similar eﬃciency.90 Moreover, the
ability of Fes from Shigella f lexneri 2a str. 2457T to hydrolyze L-
Ent and D-Ent was evaluated, and Fes did not accept D-Ent as a
substrate. As a result of the transport studies in B. subtilis and
enzymatic activity assays with S. f lexneri Fes, a model in which
both Ent enantiomers are transported and chiral recognition
occurs at the level of the esterase was proposed.90 Taken
together, these studies suggest that the ability to transport D-
Ent may vary between species and even between strains of a
given species, and more studies are required to address such
possibilities. Based on the observation that E. coli FepA binds D-
Ent and that B. subtilis transports D-Ent analogues, we
synthesized the D-enantiomers of the Ent-β-lactam conjugates
(13 and 14, Scheme 1) and evaluated the antibacterial activity
of these conjugates against E. coli K-12, 25922, CFT073, 35401,
and 43895 (Figures S9−S13). D-Ent-Amp/Amx exhibited
reduced antibacterial activity relative to Ent-Amp/Amx for K-
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12, 25922, CFT073, and 43895. Under conditions of iron
limitation, complete growth inhibition was observed with 1 μM
D-Ent-Amp/Amx for E. coli K-12, 25922, and 43895, compared
to 100 nM for Ent-Amp/Amx. Likewise, a 10-fold reduction in
antibacterial activity was observed for E. coli CFT073, where
100 nM D-Ent was required to inhibit growth completely. In
contrast, a negligible diﬀerence in antibacterial activity of the L-
and D-isomers was observed for E. coli 35401. Regardless of
enantiomer, all four Ent-Amp/Amx conjugates provide
enhanced antibacterial activity against these E. coli strains
relative to Amp/Amx. Nevertheless, these data suggest that D-
Ent-Amp/Amx are less readily transported into various E. coli
strains than the L-isomers. Although this modiﬁcation provides
no appreciable beneﬁt for this β-lactam delivery system with
periplasmic targets, it is possible that Ent-antibiotic conjugates
based on D-Ent may be desirable for delivering cargos to the
cytosol, precluding concomitant delivery of nutrient Fe(III).
The Ent-Amp/Amx β-Lactam Warhead Is Essential for
Antimicrobial Activity. With support for Ent-mediated
delivery of Ent-Amp/Amx to the E. coli periplasm, we sought
to conﬁrm the essentiality of the β-lactam warheads in
antibacterial action. We therefore designed and prepared
hydrolyzed Ent-Amp/Amx analogues 15 and 16 (Scheme 2)
where the β-lactam structure is destroyed. Hydrolysis of the
Amp/Amx-alkynes 7 and 8 was achieved in the presence of 1%
TFA with heating at 37 °C, and the decomposition products 9
and 10 were obtained as diastereomeric mixtures (Scheme 2).
The formation of these species followed the reported
degradation pathways for ampicillin, where hydrolysis and
subsequent decarboxylation occur.91 The diastereomeric
mixtures were employed to prepare the hydrolyzed conjugates
Ent-Hydro-Amp 15 and Ent-Hydro-Amx 16 via a copper-
catalyzed click reaction.
We employed Ent-Hydro-Amp/Amx in antibacterial activity
assays against E. coli K-12 and observed negligible growth
inhibition (Figure 4A). When E. coli CFT073 was treated with
Ent-Hydro-Amp/Amx in the presence of DP, growth recovery
occurred at micromolar concentrations (Figure 4B). This result
indicates that Ent-Hydro-Amp/Amx are transported into the
cytoplasm of E. coli CFT073, where nutrient iron is released.
We also performed a series of antibacterial activity assays
with E. coli ATCC 35218, a strain that expresses a class A serine
β-lactamase. Similar to unmodiﬁed Amp/Amx, Ent-Amp/Amx
were inactive against E. coli ATCC 35218 (MIC > 10 μM) in
the absence and presence of DP (Figures 4C and S14). Slight
growth inhibition was observed at 10 μM under conditions of
iron limitation, which may be attributed to iron chelation. The
addition of β-lactamase inhibitors restored the activities of Ent-
Amp/Amx and Amp/Amx, and the conjugates exhibited greater
antibacterial activity than the parent antibiotics (Figures 4C and
S14). In total, the assays with Ent-Hydro-Amp/Amx and strains
expressing β-lactamase demonstrate that an intact β-lactam is
required for the antibacterial activity of Ent-Amp/Amx.
Moreover, these studies indicate that the β-lactams retain
their original function and inhibit PBPs when conjugated to
Ent.
Time-Kill Kinetics Reveal Rapid Killing of E. coli
CFT073 by Ent-Amp/Amx. The remarkable sensitivity of E.
Scheme 2. Syntheses of Ent-Hydro-Amp/Amx
Figure 4. β-Lactam is required for Ent-Amp/Amx antimicrobial activity. (A,B) Antibacterial activity assays against E. coli K-12 (A) and CFT073 (B)
using Ent-Amp/Amx and Ent-Hydro-Amp/Amx. (C) Antibacterial activity assays against E. coli ATCC 35218, which expresses a class A serine β-
lactamase, using Ent-Amp/Amx in the absence and presence of the β-lactamase inhibitors potassium clavulanate (PC) and sulbactam (SB). All assays
were performed in 50% MHB supplemented with 200 μM DP (mean ± SEM, n ≥ 3). Additional data are presented in Figure S14.
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coli CFT073 to Ent-Amp/Amx (Figure 2C) motivated us to
investigate the relative cell-killing kinetics of Ent-Amp/Amx
and Amp/Amx to determine whether these conjugates kill E.
coli CFT073 more rapidly than the unmodiﬁed drugs. For
comparison between E. coli strains, we also evaluated the time-
kill kinetics for E. coli K-12. Ent-Amp/Amx provide more rapid
cell death than unmodiﬁed Amp/Amx (Figure 5), and this
behavior is most apparent for E. coli CFT073, where the OD600
value was almost reduced to the baseline value after 1 h
incubation with 5 μM Ent-Amp/Amx, corresponding to a 2-
fold log reduction in CFU/mL. In contrast, the change in
OD600 and CFU/mL for E. coli CFT073 treated with 50 μM
unmodiﬁed Amp/Amx is negligible over this time period. The
time-kill kinetics for E. coli K-12, conducted with 50 μM of both
unmodiﬁed and modiﬁed β-lactams, indicate a slight increase in
kill kinetics for Ent-Amp/Amx relative to Amp/Amx, and that
the kinetics of cell-killing are slower for K-12 than CFT073
(Figure 5). These results support a model whereby Ent
modiﬁcation facilitates uptake of Amp/Amx relative to the
unmodiﬁed drugs. This eﬀect is more dramatic for E. coli
CFT073 than K-12, which is in accordance with the enhanced
antibacterial activity observed for CFT073 relative to the other
E. coli strains considered in this work.
Ent-Amp/Amx Provides Species-Selective Anti-
microbial Activity. To determine whether Ent-Amp/Amx
exhibit broad-spectrum or species-selective activity, we
performed antibacterial activity assays with two additional
Gram-negative and two Gram-positive species in both the
absence and presence of DP. These species include Klebsiella
pneumoniae ATCC 13883, Pseudomonas aeruginosa PAO1, S.
aureus ATCC 25923, and Bacillus cereus ATCC 14579. K.
pneumoniae is a Gram-negative species that biosynthesizes and
utilizes Ent for iron acquisition. P. aeruginosa is a Gram-negative
bacterium that captures Ent as a xenosiderophore and expresses
two Ent receptors PfeA and PirA.92−94 S. aureus and B. cereus
are both Gram-positive bacterial species, and the ability to
utilize ferric Ent as an iron source is reported for both
species.95,96 In contrast to Gram-negative bacteria, where the
PBPs are located in the periplasm, the targets of β-lactam
antibiotics are in the extracellular peptidoglycan of Gram-
positive organisms.
K. pneumoniae ATCC 13883 has a chromosomally encoded
class A β-lactamase (SHV-1) and lacks sensitivity to Amp/Amx.
We observed no eﬀect of 100 μM Amp/Amx on K. pneumoniae
growth under our assay conditions (Figure S15). Only ∼50%
growth inhibition was observed when K. pneumoniae was
treated with high concentrations (10 μM) of Ent-Amp/Amx in
the absence of DP, and the Ent-Amp conjugate provided the
greatest activity under conditions of iron limitation with ∼90%
growth inhibition at 10 μM. When β-lactamase inhibitors were
included in the assays, K. pneumoniae exhibited greater
sensitivity to Amp/Amx (MIC = 100 μM) and Ent-Amp/
Amx (MIC = 10 μM); however, we observed some growth
inhibitory activity of the β-lactamase inhibitor sulbactam alone
under these assay conditions (100 μM SB, Figure S15). Thus,
the possibility of a synergistic eﬀect from the inhibitors and
conjugates cannot be ruled out completely. The lack of activity
of Ent-Amp/Amx against K. pneumoniae ATCC 13883 is
reminiscent of results obtained during investigations of Amp/
Amx-functionalized tripodal triscatecholate ligands.53 These
compounds were inactive against K. pneumoniae, and the
behavior was attributed to either an inability of the K.
pneumoniae iron transport machinery to import the conjugates
or the development of resistance over the course of the assay.
An alternative explanation is that β-lactamase expression by K.
pneumoniae resulted in inactivation of the β-lactams.
The P. aeruginosa PAO1 strain employed in this work
exhibited little sensitivity to both Amp/Amx and the conjugates
under the antibacterial assay conditions (Figure S16). Amp/
Amx exhibited no activity up to 100 μM, whereas Ent-Amp/
Amx provided growth inhibition at 10 μM in both the absence
and presence of DP. Whether these results indicate that Ent-
Amp/Amx will be ineﬀective against multiple P. aeruginosa
strains is unclear. P. aeruginosa strains exhibit diﬀerent
phenotypes, and highly variable and strain-dependent MIC
values have been reported for triscatecholate−β-lactam
conjugates against P. aeruginosa.53 We previously reported
that P. aeruginosa PAO1 imports Ent-cargo conjugates,66 and
we speculate that the lack of activity observed for this strain
stems from its inherent insensitivity to Amp/Amx.
B. cereus ATCC 14579 was also insensitive to Amp/Amx,
which only aﬀorded growth inhibition at 100 μM. Some growth
inhibition was observed for B. cereus treated with 10 μM Ent-
Amp/Amx, which may result from iron sequestration (Figure
S17). S. aureus ATCC 25923 is susceptible to Amp/Amx, with
complete growth inhibition observed at 1 μM. In this case, a
10-fold reduction in antibacterial activity was observed for Ent-
Amp/Amx relative to unmodiﬁed Amp/Amx (Figure 6).
Although the origins of this attenuation are unclear, we
speculate that Ent-Amp/Amx may have trouble penetrating the
thick peptidoglycan of S. aureus. An alternative possibility is that
recognition of Ent-Amp/Amx by the S. aureus Ent receptor
diverts the β-lactams from the PBPs.
In total, the results from these assays indicate that Ent-Amp/
Amx exhibit antibacterial activity enhancements that are
species-selective, providing increased potency against E. coli
strains and not for the other strains evaluated in this work. We
therefore reasoned that Ent-Amp/Amx, at low concentrations,
Figure 5. Time-kill kinetic assays for treatment of E. coli K-12 (top
panel) and CFT073 (bottom panel) with Amp/Amx and Ent-Amp/
Amx. E. coli K-12 (∼108 CFU/mL) was treated with 50 μM of Amp/
Amx or 50 μM Ent-Amp/Amx. E. coli CFT073 (∼108 CFU/mL) was
treated with 50 μM of Amp/Amx or 5 μM Ent-Amp/Amx. The assays
were conducted in 50% MHB medium containing 200 μM DP at 37
°C (mean ± SEM, n = 3).
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should selectively kill E. coli in the presence of other less
sensitive species. We treated co-cultures of E. coli CFT073 and
S. aureus with Ent-Amp/Amx or Amp/Amx and analyzed the
species composition following a 19-h incubation using HARTY-
UTI plates. These agar plates are employed in medical
microbiology laboratories for the diagnosis of urinary tract
infections and provide species identiﬁcation by the colony
color. When grown on HARTY-UTI plates, S. aureus are oﬀ-
white and E. coli are purple-pink. In Figure 6, we present
representative images of the colonies that resulted from treating
co-cultures of E. coli and S. aureus with Amp/Amx or Ent-Amp/
Amx. In the absence of antibiotic, the cultures provide a
mixture of oﬀ-white and purple-pink colonies, indicating that
both E. coli and S. aureus grow when cultured together. When
the co-cultures are treated with 1 μM Amp/Amx, only purple-
pink colonies are present, which reveals that only E. coli
survives. In contrast, treatment of the co-cultures with 1 μM
Ent-Amp/Amx results in only oﬀ-white colonies from S. aureus.
These comparisons demonstrate that Ent-Amp/Amx selectively
kill E. coli in the presence of S. aureus and that the siderophore
modiﬁcation reverses the inherent species selectivity of the
parent antibiotics. Achieving such species-selective and single-
pathogen antibiotic targeting is an important goal and unmet
need for pharmaceutical development that will allow for
treating disease with minimal perturbation to the commensal
microbiota.97,98
Ent-Amp Exhibits Low Cytotoxicity to Mammalian
Cells. We evaluated the cytotoxicity of Ent-Amp against the
human T84 colon epithelial cell line. Cell survival was evaluated
by MTT assay after a 24 h treatment with apo or iron-bound
Ent-Amp, Amp, or Ent. The iron-bound forms were assayed to
determine whether iron chelation in the growth medium is a
factor. No cytoxicity was observed for Amp or Ent-Amp,
whereas apo Ent itself decreased the survival of T84 cells by
approximately 30% at the highest concentration evaluated.
When pre-loaded with Fe(III), no cytotoxic eﬀect from Ent was
observed (Figure 7).
FepA and Lipocalin-2 Compete for Ent-Amp/Amx.
Lipocalin-2 (lcn2, also known as siderocalin or NGAL) is a 22-
kDa protein produced and released by neutrophils and
epithelial cells. It has a hydrophobic binding pocket and
coordinates ferric Ent with sub-nanomolar aﬃnity.69,85 By
sequestering ferric Ent, this host-defense protein contributes to
Figure 6. Ent-Amp/Amx selectively kill E. coli CFT073 in the presence of S. aureus ATCC 25923. (A,B) Antimicrobial activity assays against S.
aureus ATCC 25923 in the absence (A) and presence (B) of 200 μM DP. (C,D) Bacterial growth monitored by OD600 for cultures of E. coli only, S.
aureus only, and 1:1 E. coli/S. aureus mixtures treated with Amp/Amx or Ent-Amp/Amx in the absence (C) and presence (D) of 200 μM DP. The *
indicates OD600 < 0.01. (E) Representative photographs of colonies from mixed cultures of E. coli CFT073 and S. aureus ATCC 29523 treated with
Ent-Amp/Amx (1 μM) or Amp/Amx (1 μM) in the presence of 200 μM DP. All assays were conducted in 50% MHB medium (t = 19 h, 30 °C)
(mean ± SEM, n ≥ 3 for A−D).
Figure 7. Ent-Amp exhibit negligible cytotoxicity toward human T84
intestinal epithelial cells. Percent cell survival quantiﬁed by MTT assay
after a 24 h treatment with apo or iron-bound Ent, Ent-Amp, and the
parent antibiotic Amp in the absence and presence of 1 equiv of
Fe(III) (mean ± SEM, n = 3).
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the metal-withholding response and prevents bacterial acquis-
ition of this essential nutrient. To determine whether lcn2 also
binds Ent-Amp/Amx and thereby blocks antibacterial activity,
we performed antibacterial activity assays with E. coli CFT073
in M9 minimal medium supplemented with lcn2 or bovine
serum albumin (BSA). Under these conditions, up to 1 μM of
lcn2 had no eﬀect on the growth of E. coli CFT073. Addition of
1 μM lcn2 to the medium rescued the growth of E. coli CFT073
treated with 100 nM of Ent-Amp (Figure 8) whereas addition
of 1 μM BSA had no eﬀect on Ent-Amp cell killing. These
results suggest that lcn2 binds Ent-Amp and blocks its
recognition and uptake. To ascertain whether lcn2 binds Ent-
Amp in the presence of exogenous Ent, we performed a series
of experiments where E. coli CFT073 were treated with ﬁxed
concentrations of Ent-Amp (100 nM) and lcn2 (1 μM) and the
concentration of Ent was varied (0, 0.5, and 1 μM). Ent
supplementation restored the antibacterial activity of Ent-Amp
(Figure 8). Moreover, When Ent-Amp was combined with a
1:1 molar ratio of Ent and lcn2 at 10-fold excess over the
conjugate, no E. coli growth was observed, which suggests that
lcn2 preferentially binds Ent. Prior work demonstrated that
lcn2 cannot bind glucosylated Ent, which was attributed to a
steric clash between the glucose moieties and the Ent binding
site of the protein,85 and decreased hydrophobicity of the
siderophore may also be a factor. Thus, our data suggest that
the nature of linker attachment at C5 and the PEG3 moiety of
Ent-Amp/Amx do no abrogate lcn2 binding as eﬀectively as the
glucose moieties exhibited by the salmochelins.
■ SUMMARY AND PERSPECTIVES
Ent-Amp/Amx are two siderophore−β-lactam conjugates based
on the native enterobactin scaﬀold. These molecules hijack
siderophore-based iron uptake pathways and provide potent
antibacterial activity against various E. coli strains, including
human pathogens. Our investigations of Ent-Amp/Amx
establish the following: (i) Ent-Amp/Amx provide up to
1000-fold enhanced antibacterial activity against E. coli strains;
(ii) Ent-Amp/Amx are transported into E. coli by FepA and
potentially other catecholate siderophore receptors (IroN, Iha)
employed by pathogenic CTF073 and UTI98; (iii) Ent-Amp/
Amx are captured by PBPs in the periplasm, which results in
PBP inhibition and cell death; (iv) selective killing of E. coli in
the presence of less susceptible organisms such as S. aureus is
achieved because of the enterobactin scaﬀold; (v) Ent-Amp/
Amx exhibit negligible cytotoxicity to human T84 intestinal
epithelial cells; and (vi) although lcn2 has the ability to bind
Ent-Amp/Amx, this siderophore-scavenging protein prefers to
capture native Ent. In total, these studies demonstrate that
modiﬁcation of antibiotic cargo with the native enterobactin
platform provides many desirable features for antibiotic delivery
and eﬃcacy. The large molecular weight of the conjugates
resulting from the native Ent scaﬀold (as opposed to a smaller
mimic) enhances rather than diminishes uptake for Gram-
negative E. coli. Moreover, we observed no evidence for the
development of resistance to Ent-Amp/Amx over the course of
the antibacterial activity assays performed during these
investigations.
Our studies conﬁrm that the enhanced antibacterial activity
observed for Ent-Amp/Amx requires both enterobactin
recognition by outer membrane receptors and an intact β-
lactam moiety. These results are in accord with expectations.
The results are reminiscent of the dramatic antibacterial activity
enhancements observed for albomycin, a secondary metabolite
produced by Actinomyces subtropicus. Albomycin is comprised of
the siderophore ferrichrome and a tRNA synthetase inhibitor,
and it exhibits antimicrobial activities that are 30,000-fold
greater than those of the unmodiﬁed tRNA synthetase inhibitor
against E. coli and S. aureus.99 Nonetheless, the Ent-Amp/Amx
cell-killing mechanism may be more complex than only more
eﬃcient β-lactam delivery across the Gram-negative outer
membrane. Binding of Ent-Amp/Amx to the PBPs presumably
results in accumulation of ferric enterobactin in the E. coli
periplasm for some period of time, which may have deleterious
consequences. A recent study of an E. coli tolC- mutant revealed
that enterobactin accumulation in the periplasm aﬀords growth
defects and abnormal cellular morphologies.100
A fascinating observation that stems from our current work is
the variable susceptibilities and responses of diﬀerent E. coli
strains to Ent-Amp/Amx, which contrast the eﬀects of
unmodiﬁed Amp/Amx. Such diﬀerences are manifest in the
MIC values to some degree and time-kill kinetics; however, the
results presented in Figure 2 indicate that MIC values alone do
not provide a full description of how Ent-Amp/Amx
susceptibility diﬀers between E. coli strains. These results
suggest underlying complexity in microbial physiology related
to iron-uptake pathways that cannot be fully explained by the
Figure 8. Antibacterial activity of Ent-Amp against E. coli CFT073 in the presence of lcn2 or BSA. (A) E. coli CFT073 treated with 100 nM Ent-Amp
and varying concentrations of lcn2 or BSA control. (B) E. coli CFT073 treated with Ent-Amp, varying concentration of Ent, and varying
concentrations of lcn2 or BSA control. The assays were performed in M9 minimal medium (24 h, 37 °C) (mean ± SEM, n ≥ 3). The ** indicates
OD600 < 0.01.
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presence or absence of a gene for a particular receptor (i.e.,
FepA, IroN). The heightened sensitivity of uropathogenic E.
coli CFT073 is particularly noteworthy, and it will be interesting
to decipher the physiological origins of this eﬀect as well as the
diﬀerential behavior of various E. coli pathogens toward Ent-
antibiotic conjugates.
There is a clear and unmet need for new antibacterial agents
to treat bacterial infections in humans, including antibiotics that
target speciﬁc bacterial sub-populations.1−5 Preventing undesir-
able consequences of antibiotic treatment on the commensal
microbiota, which contributes to human health in beneﬁcial
ways, is a challenge that needs to be addressed.97,98 Such
targeted therapeutics will be valuable not only for treating
bacterial infections when the causative agent is known (e.g.,
urinary tract infection and E. coli, cystic ﬁbrosis lung infection
and P. aeruginosa) but also for other pathologies that involve
microbial dysbiosis, such as irritable bowel disease.101 Our
studies of Ent-Amp/Amx provide one step toward addressing
species-speciﬁc antibiotic targeting as well as overcoming
Gram-negative outer membrane permeability. From the
standpoint of the host environment, commensal E. coli employ
Ent for acquiring iron in the host, and thus further elaboration
of this strategy to speciﬁcally target pathogenicity and evade
host responses (e.g., lcn2) is desirable. Eﬀorts along these lines
are in progress.
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